Research Article
Bromhexine Hydrochloride Prophylaxis of COVID-19 for Medical Personnel: A Randomized Open-Label Study
Table 2
Study outcomes: positive PCR tests and COVID-19.
| | | Bromhexine treatment group | Control group | Overall | |
| n | | 25 | 25 | 50 | 1.00 | Primary outcome (positive PCR test or COVID-19) | | 2 | 7 | 9 | 0.07 | Positive SARS-CoV-2 PCR test, n | | 2 | 7 | 9 | 0.07 | | Asymptomatic | 2 | 2 | 4 | 1.00 | | Symptomatic | 0 | 5 | 5 | 0.02 | COVID-19 moderate, n | | 0 | 3 | 3 | 0.08 | COVID-19 severe with hospitalization, n | | 0 | 2 | 2 | 0.16 | Drug nonadherence | | | | | | | Missed doses of bromhexine, n | 4 | — | — | — | | Number of missed bromhexine doses, median [IQR] | 6 [5.25; 7.5] | — | — | — | Adverse events, n | | 2 | 0 | 2 | 0.16 |
|
|
n, number of participants; IQR, interquartile range; PCR, polymerase chain reaction.
|